Business Standard

Wanbury Share Price

Know More
NSEBSE

153.65-6.00 (-3.76%)

03:49 PM,12th Apr 2024

154.00-5.10 (-3.21%)

04:01 PM,12th Apr 2024

BSE : 524212

NSE : WANBURY

Sector : Health care

ISIN Code : INE107F01022

  • NSE
  • BSE
  • 1D
  • 5D
  • 1M
  • 6M
  • 1Y
  • 2Y
  • 5Y
  • MAX

Last Updated: Apr 12 2024 | 04:01 PM IST

Market Cap (₹ Cr)

503

Turnover (₹ Cr)

0.29

Volume (Shares)

186427

Face Value

10

52-WK High

179.35

52-WK High Date

28 Feb 2024

52-WK Low

33.60

52-WK Low Date

18 Apr 2023

All Time High

179.35

All Time High Date

28 Feb 2024

All Time Low

10.75

All Time Low Date

25 Oct 2019

Wanbury Ltd

Wanbury Ltd (Formerly known Pearl Organics Limited) was incorporated in August 1988. The Company is engaged in the business of pharmaceutical and related activities including research.The company has established its first plant in the year 1992 in Tarapur for manufacturing APIs. In 1995 the Company acquired plant of Brij Chemicals Pvt Ltd at Patalganga. In 1996 it entered into a strategic alliance with Wyckoff Chemicals to manufacture its API in US.In 2007-08 the merger of Doctors Organic Chemicals Limited (DOCL) with the Company became effective from 1st April 2007. Pursuant to the aforesaid Order of the Hon'ble Bl FR 785557 Equity Shares of face value of Rs. 10/- each of the Company were issued to the Equity Shareholders of DOCL on 17th March 2008. Similarly the Pharmaceutical Products of India Limited (PPIL) was merged with the Company effective from April 1 2006. In terms of the said Scheme of Merger the Company had issued 562618 Equity Shares of face value of Rs. 10/- each to the Equity Shareholders of PPIL on 27 June 2007 which got listed on Bombay Stock Exchange Limited and National Stock Exchange Limited respectively.The company entered into a strategic association with Bravo Healthcare Ltd and incorporated Ningxia Wanbury Fine Chemicals Co Ltd to source raw materials from China. It opened its office in ZurichSwitzerland for its CRAMS business and incorporated Wanbury Global FZE in Middle East for carrying out its trading activities in the year 2008.The novel product 'Cdense Gems' was launched in May 2008. The Company completed the restructuring of the Formulation Division during the year 2013. It launched Myotol-F targeted at female infertility in 2013 it launched Folinine. The Company's newly launched products Myotol-F (to treat polycystic ovarian syndrome) and Cal-K2 (in prevention and management of Osteoporosis) were labelled as one of the best launches in 2014.

Wanbury Ltd - Key Fundamentals

PARAMETER VALUES
Market Cap (₹ Cr)

548

EPS - TTM (₹) [S]

7.31

P/E Ratio (X) [S]

170.97

Face Value (₹) 10
Latest Dividend (%)10.00
Latest Dividend Date 29 Jul 2010
Dividend Yield (%) -
Book Value Share (₹) [S]0.98
P/B Ratio (₹) [S]170.97
[*C] Consolidated [*S] Standalone

Funds Owing this Stock

Scheme Name Amount Invested ( ₹ Cr ) No Of Shares Net Asset (%)
UTI-Unit Linked Insurance Plan 0.03 10002 0.00
UTI-Unit Linked Insurance Plan - Direct 0.03 10002 0.00

Research Reports

Date BrokerActionPrices(Rs)Report
Data Not Found

Stock Strength

Today's Low/High

152.00

161.40

Week Low/High

151.00

175.00

Month Low/High

123.00

175.00

Year Low/High

33.60

179.00

All time Low/High

0.85

179.00

Share Price Returns

Period BSENSE SENSEXNIFTY
1 Week-7.69%0.00%0.000.03%
1 Month9.28%20.80%0.780.82%
3 Month14.15%24.48%2.312.85%
6 Month95.58%111.95%11.8013.77%
1 Year306.80%341.50%22.9426.43%
3 Year60.14%72.82%55.0557.36%

Company Info

Company Information

Independent Director : N K Puri

Vice Chairman & Whole Time Dir : K Chandran

Company Sec. & Compli. Officer : Jitendra J Gandhi

Independent Director : Pallavi Shedge

Independent Director : Pravin Dilip Pawar

Registered Office: BSEL Tech Park B-Wing 10th Flr, Sector 30 A Opp Vashi Rly Stat,Navi Mumbai,Maharashtra-400703 Ph: 91-22-67942222

Email:shares@wanbury.com; jitendra.gandhi@wanbury.com

URL:http://www.wanbury.com